101 results about "Mucosal cell" patented technology

A topical pharmaceutical or cosmetic composition for treatment of irritation of mucous cells such as mucosal cells of the eye, nose, and vagina is disclosed. The composition comprises an aqueous solution of at least one polyol selected from the group consisting of xylitol, myoinositol and mannitol and at least one substance selected from the group consisting of glycerol and urea. The composition contains less than 0.01% inorganic salt and is free of any oil-in-water or wax-in-water emulsion. In particularly preferred embodiments, the composition comprises an aqueous solution containing 1.5-5% (w / v) xylitol and 0.9-2.0% (w / v) glycerol.

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

What is described is a method of delivering PTH to a human, comprising exposing a layer of mucosal cells to a mixture of PTH and an enhancer, wherein the enhancer is capable of modulating the barrier function of a cellular tight junction. Specifically, the method of delivering PTH to a human by intranasal administration comprises use of an aqueous solution of growth and excipients in a bottle and a droplet-generating actuator attached to the bottle and fluidly connected to the PTH solution in the container, wherein the actuator produces a spray of the PTH solution through a tip of the actuator when the actuator is engaged, wherein the spray of PTH solution has a spray pattern ellipticity ratio of from about 1.0 to about 1.4 when measured at a height of 3.0 cm from the actuator tip.

The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp. or coccidia sp based diseases or other enteric diseases or by generally improving gastro intestinal health or function

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

The invention belongs to a feed, and particularly relates to a compound feed for enhancing the physiological functions of intestinal mucosa and liver / pancreas cells of fishes, which contains fish meal, soybean meal, rapeseed meal, cottonseed meal, wheat, rice bran, rice bran meal, calcium biphosphate, zeolite powder, bentonite, DL carnitine, soybean oil, vitamin-mineral premix, ursodeoxycholic acid, taurine, glutamine and yeast culture. An experimental fish raised with feed, which serves as an experimental fish for the separation and primary culture of intestinal mucosa cells and liver cells,can obtain healthy intestinal mucosa cells and healthy liver cells, moreover, the physiological condition of the experimental fish can be kept in consistency, and the repeatability of a separation and primary culture experiment on the intestinal mucosa cells and the liver cells.

The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided.

The present invention provides methods and compositions for inhibiting influenza infection and / or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and / or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.

The present invention belongs to the field of tissue engineering and medical material technology, and is especially titanium net with fimbrin coating and its preparation process and application in reconstructing trachea default. The present invention prepares fimbrin-titanium net complex with medical titanium net as support material and fimbrin to form coating. Fimbrin has excellent biocompatibility and can promote the growth of fibroblast and mucosa cell, speed healing, reduce complications. Clinically, the present invention is used in repairing trachea default. The present invention is significant in the research of fimbrin in promoting repair of trachea mucosa, reconstructing trachea default and reducing complications during reconstructing trachea default.

A pharmaceutical composition is provided for use in the healing of cells containing about 0.0001 percent weight per volume (% w / v) to about 2% w / v of an alginic acid or a salt of alginic acid having a molecular weight in the range of greater than about 250,000 to about 1,000,000, provided that if the composition additionally contains an alginic acid or a salt of alginic acid having a molecular weight in the range of about 20,000 to about 250,000, it is present in an amount of less than 1% w / w. The use of the pharmaceutical composition for the healing cells in a mammal, preferably mucosal cells is also provided.

The invention provides a method for isolating and culturing human olfactory mucosa mesenchymal stem cells. The method comprises the following steps: 1, preparing a basic culture liquid by mixing DMEM and F12 in the ratio of 1:1; 2, immediately collecting AS of a patient; 3, adding the collected AS into the human olfactory mucosa mesenchymal stem cell culture medium, and adding 3 to 7 percent of CO2 at the temperature of 35 to 38 DEG C. By adopting the method, the high-purity olfactory mucosa mesnchymal stem cells can be efficiently and rapidly obtained, the cells have strong cloning forming capacity, self updating capacity and multi-direction differential potential. The olfactory mucosa cells acquired through the method are strong in grease forming capacity, bone forming capacity, neural stem cell forming capacity and nerve cell forming capacity, and a novel method is provided for obtaining a great amount of stem cells which are applied to the cell and tissue regeneration.

Disclosed is a composition for application to skin or mucosa comprising alginic acid and / or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and / or salts thereof that contains substantially no low-molecular-weight fraction having a molecular weight of 3,500 or less.

The invention provides a divalent hemokinin-iron oral liquid, the preparation method thereof comprises: separating hematid out of blood of livestock or poultry, adding doubleness distilled water, combining ultrasonication to break wall, releasing hemoglobin, adjusting pH value of hemoglobin solution, adding protease, placing in a vacuum dry chamber, leading in pulse current for acting for 4 hours,carrying out heating enzyme killing treatment at 95 DEG C for 30 minutes, obtaining divalent hemokinin-iron with purity more than 90% by metal-chelating affinity chromatography and electromagnetic separation, then adding tomato juice, red date juice, liquorice juice, angelica sinensis juice, astragalus mongholicus juice, juice of dried rhizome of rehmannia, stevioside, glycoprotein, carrageenan and algae ester sodium to blend so as to obtain the hemokinin-iron oral liquid. The oral liquid beverage product prepared by the invention has small dose, good mouth feel and high portability, can be directly absorbed by intestinal mucosal cells, cannot directly generate any digestion characteristic irritation symptom, and the absorptivity is high.

The invention discloses a medicament for treating urinary tract infection and a preparation method thereof. The preparation method comprises the following steps of: adding polygonum aviculare, pink herb, mongolian dandelion herb, dahurian patrinia herb, heartleaf houttuynia herb, root of red-rooted salvia, red paeony root, poria, oriental waterplantain rhizome, liquoric root, lalang grass rhizome, ricepaperplant pith, himalayan teasel root, Chinese dodder seed, Chinese taxillus twig, chicken's gizzard-membrane, medicated leaven and spreading hedyotis herb into 80 to 100 weight parts of clean water; decocting the materials over mild fire for 0.5 to 1.5 hours; repeatedly decocting for three times; mixing the three-time filtrate; and packaging the mixture into bags of 500ml to prepare oral liquid so as to obtain finished products. The medicament has good effect of treating the urinary tract infection and prostatic hypertrophy (prostatitis). Compared with antiphlogistic western medicine, the medicament has small side effect and good antiphlogosis effect, and can improve and repair mucosal cells which urinate a lot and enhance the immunologic function of human bodies by activating blood and dissolving stasis, promoting digestion and treating stranguria and promoting diuresis, thereby promoting the quick recovery of the urinary tract and the prostate.

The invention provides compositions and methods useful for treating disorders treatable by producing a protein in a regulatable manner in a mucosal cell or tissue of an animal. The treatment methods include in vivo and ex vivo methods, including transplanting in vitro transformed cells that secrete the protein into a mammalian subject.

The invention relates to a nutrition composition with the function of supplementing iron and a preparation method thereof. The nutrition composition comprises the following powder components by weight percentages: 40-50% of wheat germ powder, 10-20% of bamboo shoot, 2-8% of walnut kernel, 2-8% of kelp, 2-8% of carrot, 2-8% of dried edible fungus and 2-8% of jujube, which are mixed with 5-15% of poultry eggs that are sterilized, dried and made into powder to obtain a mixture, the mixture is added with 1-3% of a flavoring agent for cooking, and then added with 0.01-0.125% of chalybeate heme iron, evenly mixed, packaged and sterilized to obtain the finished product. The heme iron contained in the nutrition composition is directly absorbed by intestinal mucosal cells, and has high absorptivity. The nutrition composition is made from natural raw materials, contains various nutritive materials essential to human body, and can consciously supplement iron while eating. The preparation method of the nutrition composition has the advantages of precise selection of raw materials, scientific formula, reasonable process and high operability.

This invention relates to a method of producing an auto induced biological barrier against spermatozoids and / or other microorganisms including viruses and / or pre cancers or non invasive cancers involving the production of an autoimmune reaction in a host in need of such auto-inducement. The invention is characterized in that it comprises the steps of producing heat shock proteins inside vaginal and cervical mucosal cells and releasing said heat shock proteins into the vaginal cavity thus inducing an autoimmune response through a trigger and / or stimulation of both innate and adaptive systems and, as a consequence, the production of: a contraceptive effect through the elimination of the migration or free movement of individual or populations of spermatozoids and / or an inhibition of the maturation and / or capacitation process of the same and / or a neutralization or destruction of the same; a prophylactic effect through an elimination of the migration or free movement of individual or populations of other microorganisms including viruses and / or a neutralization or destruction of the same; a prophylactic effect against pre cancers; a therapeutic effect against non invasive cancers. The invention also relates to a device for using said method comprising a hollow body (1) provided with a heat source on the inside as well as with a means (13, 27) of removal of said hollow body from the vaginal or rectal cavity and a means (6, 8, 10) capable of exchanging heat originating from the hollow body.

The invention belongs to the field of separation and culture of intestinal mucosal cells of animals, and particularly relates to a method for separation and primary culture of intestinal mucosal cells of fishes. The method comprises two steps of preparing materials, namely taking fish intestines out according to the conventional method, removing the fat outside the intestines, and digesting and separating the intestinal mucosal cells of fishes by any of the following two methods to obtain digestive juice containing free mucosal cells and cell mass, and centrifuging the obtained digestive juice containing free mucosal cells and cell mass to obtain the mixture of mucosal cells and cell mass which is used as inoculating material cells for primary culture; and culturing, namely performing primary culture by using skin collagens as a culture support vector, using the improved Dulbecco's modified Eagle medium (DMEM) liquid as a culture medium, and using the improved D-Hanks liquid as balanced salt solution at the culture temperature of between 26 and 28 DEG C and pH value of between 7.2 and 7.4 for more than 24 hours, namely attaching to the surface to ensure that the cells grow. The obtained intestinal mucosal cells of fishes grow well, and the structure and functional marking index system is perfect.

The invention belongs to the technical field of biology and particularly discloses an oral cancer detection marker and an oral cancer detection kit. The levels of mRNA of CDC6, CDT1, MCM2 and CDC45 in buccal mucosal cells of a normal person, a person with oral inflammation, a person with precancerous lesions, a person with oral cancer and a person at the postoperation period are quantitatively detected, the detection shows that CDC6, CDT1, MCM2 and CDC45 are ideal tumor markers for the screening of the oral cavity in the early stage, and the normal buccal mucosal cells and the canceration exfoliated cells are effectively distinguished. The oral cancer detection marker and the oral cancer detection kit are of great significance for the exploration of the mechanism of the content change of the tumor marker in the buccal mucosal cells and the clinical value of prognosis judgement.

The present invention discloses the preparation process of ZQ biological membrane with natural structure. The ZQ biological membrane has excellent cell affinity and its decomposition product has no poisoning to cell and degradation rate adaptive to tissue regeneration speed, so that the ZQ biological membrane is an excellent cradlle material. It can be used in planting and bridging of peripheral nerve, repair of ligament, repair of bone and soft tissue holes, etc. and has practical significance in the tissue engineering of peripheral nerve and excellent application foreground.

The invention discloses a novel wound self-healing biological material, a preparation method and application thereof, and relates to the technical field of biological materials. The wound self-healing biological material comprises a solid component and a liquid component, wherein the solid component comprises a cationic water-soluble chitin derivative which is a chitin derivative soluble in purified water, and accounts for 0.1 to 100 weight percent of the total weight of solid component. The novel wound self-healing biological material has the advantages that the structure and performance of a molecular scaffold of the cationic water-soluble chitin derivative is close to those of skin and mucosal intercellular matrix mucopolysaccharide (such as hyaluronic acid), and is an excellent matrix material for the growth of skin and mucosal cells, and the self-healing of human skin and mucosal injury is promoted effectively by the antibiotic property of cationic macromolecules.

The invention discloses a lipoteichoic acid from clostridium butyricum and an application thereof in adjusting an immune response of livestock and poultry. The lipoteichoic acid is obtained by the steps of firstly preparing a TX-114 solution with a mass percentage of 1.5-2.5% for use; then layering 8-16 mL of a clostridium butyricum solution cultured for 45-50 h by centrifugation to obtain wet weight of clostridium butyricum; adding the TX-114 solution; centrifuging to obtain a crude extract of lipoteichoic acid; and then separating through column chromatography on a DEAE-cellulose chromatographic column. The lipoteichoic acid can improve intestinal immune functions of the livestock and poultry, suppress adhesion and attachment of pathogenic bacteria on surfaces of intestinal mucosal cells, reduce incidence of intestinal infectious diseases and increase economic benefits of livestock and poultry industry.

A screening test to identify women carrying a lethal genetic trait that predisposes to recurrent spontaneous pregnancy loss. The test method involves the quantitative determination of the frequency of highly skewed X chromosome inactivation in DNA derived from tissue cells of female patients, relative to appropriate normal control women. "Highly skewed" is defined as preferential use of one chromosome in at least 90% of the patient's cells being tested. Suitable test tissues include, but are not limited to, peripheral leukocytes, oral mucosal cells, and biopsy material.

The invention discloses a short peptide total nutrient composition and a preparation method thereof. The short peptide total nutrient composition comprises the following raw materials in parts by mass: 20-35 parts of short peptide, 45-50 parts of maltodextrin, 10-20 parts of non-dairy creamer, 2-8 parts of complex minerals, 0.3-0.6 part of multi-vitamins, 3-8 parts of a sweetener, 1-2 parts of anedible flavor, and 0.2-0.5 part of xanthan gum. The short peptide total nutrient composition is comprehensive and balanced in nutrition, can be used as the only source of nutrition and is easy to digest and absorb by a human body, the intestinal absorption mechanism is fully used, and the absorption is quicker and complete without leaving any residue in intestines. Wheat oligopeptides are rich inglutamine which is a nutrient for intestinal mucosal cells, and can prevent intestinal mucosal atrophy. The nutrient composition is suitable for people with restricted eating, digestion and absorptiondisorders, and metabolic disorders, especially for patients with severe metabolic disorders and gastrointestinal dysfunction.

The invention discloses application of an MCU (microprogrammed control unit) inhibitor in preparation of a medicine for preventing or treating intestinal ischemia-reperfusion injury, and relates to the technical field of biological medicine, and the MCU inhibitor comprises one or two of a reagent for inhibiting MCU gene expression and a reagent for inhibiting MCU protein activity. The MCU inhibitor disclosed by the invention is beneficial to relieving intestinal mucosa injury and inflammatory change of intestinal tissues, improving completeness of a villus structure, reducing pathological injury degree score of the intestinal tissues and relieving cell apoptosis degree in the intestinal tissues, so that the MCU inhibitor is beneficial to relieving programmed death of intestinal mucosa cells; as a main component, the pharmaceutical composition is beneficial for preventing or treating intestinal ischemia-reperfusion injury.

The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.

A method of enhancing expression of a desired protein at mucosal effector sites, the method including placing the protein to be expressed under the control of a promoter having SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, or a fragment or variant of any of these that has promoter activity, and causing expression in mucosal cells. Constructs used in the methods, as well as suitable recombinant gut-colonising microorganisms such as a Salmonella spp., are also described. Such organisms are useful in the preparation of vaccines.

The invention relates to a human-like collagen gel for repairing a gynecologic mucosa. The human-like collagen gel comprises the following ingredients: 0.1-1wt% of human-like collagen, 0.9-1.1wt% of Carbomer, 20-25wt% of glycerinum, 0.001-0.01wt% of sodium hyaluronate, 0.05-0.1wt% of sodium hydroxide, 0.1-0.5wt% of ethylparaben, 0.2-1wt% of chitosan and the balance of water. When the human-like collagen gel disclosed by the invention is applied to an epidermis of a gynecologic position with the damaged mucosa, the transdermal absorption of the human-like collagen can speed up more dramatically. Therefore, the human-like collagen gel disclosed by the invention can better nourish and stimulate mucosal cell regeneration and promote the mucosa of the damaged gynecologic position to be repaired.